logo
I'm a dentist — here are 4 things I'd never do (and 4 tips I always recommend to patients)

I'm a dentist — here are 4 things I'd never do (and 4 tips I always recommend to patients)

Yahoo22-04-2025
Good oral health is intimately connected to our overall well-being — healthy teeth and gums play an important role in preventing chronic disease by lowering risks linked to heart disease, diabetes, and chronic respiratory diseases, among others.
April is National Oral Health Month and this month, the Canadian Dental Association (CDA) is raising awareness about the importance of oral health. To find out how Canadians can boost their oral health care routines, Yahoo Canada spoke to Dr. Sanjukta Mohanta, a general dentist practicing in the Greater Toronto Area.
Good oral health comes down to three key elements, Mohanta said. "Every Canadian can have a healthy smile by doing three things: having good daily oral hygiene, having a healthy diet that's low in sugar, and visiting a dentist at least once a year."
To find out four things Mohanta would never do, and four things she recommends to boost oral health, read on. She also shares her top dentist-approved picks for oral health care, including her favourite toothpaste, CDA-approved mouthwash, and more.
"No matter how tired I am, I will drag myself to the washroom and brush and floss," Mohanta told Yahoo Canada. "I can't fall asleep without doing it."
"People are 3D printing their own clear [teeth-straightening] liners, or they are putting elastic bands around their teeth to close spaces," she said. "Any movement of teeth should be supervised by an orthodontist, because you can create a lot of damage."
She would also skip DIY teeth-whitening methods that are touted online, like mixing baking soda and strawberries and putting them on your teeth, which is not effective and can actually be damaging. "The strawberries have sugar and acid," she said.
In fact, any online advice should be double-checked with a healthcare provider. "We have to make sure the things we do are backed by science," Mohanta said. "For example, charcoal toothpaste is really abrasive, so it's going to lead to tooth sensitivity because it's going to brush away your enamel. Instead of using charcoal toothpaste to whiten your teeth, talk to your oral healthcare provider. The whitening agents that we suggest will provide you with a whiter smile without damaging your teeth."
"We should avoid buying products that don't have the Canadian Dental Association (CDA) seal of approval," Mohanta said. "Products with the CDA seal of approval mean they have done tests to make sure that the product is safe, and it's effective at actually doing what it says it's supposed to do."
"We should avoid using medium and hard-bristled toothbrushes because they are way too abrasive," she said. "You could actually brush away your gum and create notches in your enamel, and that'll create sensitivity."
Instead, always buy brushes with soft bristles, and do not brush hard. "We should not scrub by the gum line. That'll brush away the gums and cause sensitivity," she said. "We should use a light touch and brush in little circles by the gum line and then sweep away."
"It's really important to visit your dentist at least once a year," Mohanta said. "Don't wait until you have pain, because by that time, you'll need expensive treatment."
With this in mind, starting on May 1, the Canadian Dental Care Plan is expanding to include all Canadians aged 18 to 64 who do not have access to dental insurance and bring in under $90,000 per year. "Apply if you're eligible," Mohanta suggests.
"I wish people would use therapeutic mouthwashes more often, like Listerine," Mohanta said. "It doesn't just fight bad breath. It also decreases plaque and gingivitis, and if it has fluoride in it, like Listerine Total Zero, it will help decrease decay, on top of decreasing gum disease and bad breath."
Mohanta said swishing with CDA-approved mouthwash only takes 30 seconds twice a day. "It's really easy to do. All you have to know is how to swish. And the evidence shows that it reduces plaque by 52 per cent more than if you just brush and floss. If you add Listerine to brushing and flossing, you're going to remove more plaque for a healthier mouth."
For those who are put off by really intense mouthwash, Mohanta suggests opting for the milder versions, such as Listerine Zero, which has no alcohol in it, or Listerine Green Tea Zero. "That's a really mild flavour mouthwash and it tastes great, like a matcha mouthwash."
"I wish people drank more water," Mohanta said. "Water is the main drink that we should be drinking every day, all day long." Mohanta says water should be everyone's go-to beverage because it has no sugar, it doesn't cause cavities, and, unlike flavoured drinks, some water contains fluoride, which can help prevent tooth decay.
"Drinking water prevents our mouths from drying, and it helps to wash away food that's stuck to our teeth. Water is also going to decrease gum disease and tooth decay — just from washing stuff off of our teeth and moistening our mouth," she said.
However, if you choose to drink sugary drinks like soda or juice, here's a dentist-approved hack.
"The trick is to drink it quickly, so that way it's not on your teeth for very long. So, if you're going to have sugary drinks, it's better to drink them within half an hour instead of sipping on them all day. If you sip it all day, you're exposing your teeth to the acids all day, versus if you drink it quickly, you're exposing your teeth to it for just a short time."
Afterwards, rinse your mouth with water — that simple act can help reduce any sugars lingering on your teeth.
In an ideal world, people should avoid eating sweet and sticky food to limit the amount of sugar on their teeth. However, even Mohanta indulges in a sweet treat. "I love sweets. I eat them every day, but I practice harm reduction," she said. "I will pick sweets that aren't sticky. For example, at Easter, I pick the pure chocolate, because that's not going to stick to my teeth like candies or caramel would."
After she eats anything sweet, she follows up with a piece of hard cheese or a crunchy fruit or vegetable, like apples, carrots or cucumbers. "These help naturally clean it off your teeth. And if I can't do that, I'll rinse my mouth with water."
If you are snacking on sweet treats, Mohanta recommends exposing your mouth to sugar for a limited time only. So if you're having a movie night with a bowl of Hershey's Kisses, for example, Mohanta suggests eating them faster.
"It's actually better for your teeth to eat it all at once. Just expose your mouth to the sugar for five minutes, instead of two hours," she says.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

Yahoo

time20 minutes ago

  • Yahoo

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The Food and Drug Administration (FDA) approved ORLYNVAH™ for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options in October 2024. ORLYNVAH™ is the first oral penem antibiotic commercially available in the U.S. and the first new branded product to be introduced in the U.S. for uUTI in more than 25 years – offering a critical option for patients and physicians facing a shrinking arsenal of effective oral therapies. Sixty percent of women experience a urinary tract infection in their lifetime and 44% experience three or more episodes annually. It is the most common outpatient infection in women in the United States, and resistance continues to increase. According to a 2024 U.S. study in approximately 150,000 patients with uncomplicated UTIs: 57% of initial infections were resistant to at least one antibiotic class; and 13% were resistant to three or more. Without new, safe and effective oral therapies, resistant uUTIs are expected to inflate healthcare costs and may lead to poor patient outcomes in the U.S., including the need for additional courses of therapy, emergency room visits or hospitalizations, all of which underscore the urgent need for innovation in this space. 'The availability of ORLYNVAH™ is tremendous news for clinicians and patients alike,' said Marjorie Golden, MD, FIDSA, Site Chief, Infectious Disease, St. Raphael Campus Yale New Haven Hospital. 'The launch of ORLYNVAH™ provides a new treatment option with impressive efficacy data to treat appropriate adult women suffering from difficult-to-treat uUTIs.' Dr. Golden added, 'For patients who currently have limited treatment options, ORLYNVAH™ provides a long overdue oral alternative that allows for treatment in the community. This paradigm shift in the management of patients with uUTI will not only reduce emergency department visits and hospital admissions, but it will also favorably impact patients' quality of life.' 'Our mission is to create new antibiotics for patients and to be a treatment alternative to address substantial unmet medical needs in the community,' said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. 'For many people with multidrug-resistant uUTIs, options have been exhausted. We're proud to introduce ORLYNVAH™—the first oral penem ever approved by the FDA—giving clinicians and patients a much-needed new therapy.' To support patient access, Iterum Therapeutics is launching a copay savings program allowing eligible patients to obtain ORLYNVAH™ for as little as $25. For more information about ORLYNVAH™, including full prescribing information, please visit Uncomplicated urinary tract infections (uUTIs) are a common bladder infection typically confined to the lower urinary tract in otherwise healthy women with no structural abnormalities of the urinary tract—caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis. About Iterum Therapeutics plcIterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit About ORLYNVAH™ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. Cautionary Note Regarding Forward-looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™ and the success of Iterum's commercialization of ORLYNVAH™ in the U.S. In some cases, forward-looking statements can be identified by words such as 'may,' 'believes,' 'intends,' 'seeks,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'should,' 'assumes,' 'continues,' 'could,' 'would,' 'will,' 'future,' 'potential' or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's successful commercialization of ORLYNVAH™ in the U.S. with its commercial partner, EVERSANA, including Iterum's ability to maintain and continue to build a sales force for the commercialization of ORLYNVAH™ in the U.S., the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if the commercialization of ORLYNVAH™ in the U.S. is unsuccessful, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, the potential impact of resistant uUTIs on healthcare costs and medical outcomes for uUTI patients in the U.S., Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption 'Risk Factors' in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. PRESS CONTACTJennifer PerciballiOak+Cannon PR for Iterumjennifer@ Investor RelationsJudy MatthewsChief Financial Officer Iterum Therapeutics 312-778-6073IR@

Vegetarianism associated with decreased cancer risk
Vegetarianism associated with decreased cancer risk

Yahoo

time31 minutes ago

  • Yahoo

Vegetarianism associated with decreased cancer risk

Cancer is the second leading cause of death globally, accounting for 1 in 6 deaths worldwide in 2018, according to the World Health Organization. Cancer is caused by both genetic and environmental factors, which vary depending on cancer type. Diet is known to be a major risk factor for multiple cancers, with processed and red meat being a risk factor for bowel cancer. Previous studies have explored the association between vegetarianism and multiple common cancers, but associations with less common cancers have yet to be explored, and in research published in The American Journal of Clinical Nutrition, Gary Fraser and colleagues used cohort study data from The Adventist Health Study-2 (AHS-2) to assess the relationship between vegetarianism and risk of different uncommon and common cancer types. The study found that vegetarians had a 12% lower risk of developing cancer overall compared to non-vegetarians. To observe the effects of diet and the odds of developing cancer, the study collected baseline data of participants from the AHS-2. This cohort study recruited more than 95,000 US and Canadian participants between 2002 and 2007, all of whom were volunteer members of the Seventh-day Adventist church. Dietary habits were obtained from a validated food frequency questionnaire. Vegetarians included those categorised as vegans (who avoided all animal products, consuming fewer than one such product per month), lacto-ovo-vegetarians (who avoided meat and fish but consumed eggs/dairy once or more per month), and pesco-vegetarians (who avoided meat but consumed eggs/dairy/fish once or more per month). Cancer diagnosis (identified using the International Classification of Diseases version 10 and International Classification of Diseases, Oncology codes) was obtained by matching the AHS-2 data to cancer registries, with follow-up lasting from 2010 to 2013, depending on the US state and Canadian province/territory. In total, 79,468 participants were included in the study. Compared to non-vegetarians, vegetarians had a 12% lower risk of developing cancer overall. Vegetarians were also shown to have decreased risk of bowel cancer development, with a 45% lower risk of developing stomach cancer, a 20% lower risk of developing colon cancer, and a 21% lower risk of developing colorectal cancer. Other than bowel cancers, vegetarians had a lower risk of lymphoma and lymphoproliferative cancers compared to non-vegetarians, both with a 25% decreased risk. The study by Fraser and colleagues provides further evidence of vegetarianism being a protective factor against bowel cancers, and also provides new evidence for vegetarianism being a protective factor against lymphoproliferative cancers. The study therefore provides an incentive to explore what aspects of vegetarianism protect against these cancers specifically. However, it is important to note that information on dietary habits was taken at the beginning of the study, which was subject to change during follow-up. GlobalData epidemiologists forecast that in the 16 major markets (16MM: Australia, Brazil, Canada, China, France, Germany, Italy, Japan, India, Mexico, Russia, South Africa, South Korea, Spain, the UK and the US), five-year diagnosed prevalent cases of colorectal cancer in men and women aged 18 years and over will increase from 4.6 million in 2025 to 5.4 million in 2031. "Vegetarianism associated with decreased cancer risk" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TB screenings at two pre-schools after staff member diagnosed in July
TB screenings at two pre-schools after staff member diagnosed in July

Yahoo

time2 hours ago

  • Yahoo

TB screenings at two pre-schools after staff member diagnosed in July

SINGAPORE - Tuberculosis (TB) screenings will be conducted at two pre-schools after an individual working at both locations was found to have been diagnosed with the bacterial disease, the Communicable Diseases Agency (CDA) has said. In response to queries, CDA said on Aug 13 it was notified on July 15 of the positive diagnosis of a staff member who worked at MapleBear Toa Payoh and MindChamps PreSchool's East Coast branch. It then began contact tracing to 'ensure early detection and treatment, and to curtail the spread of TB', the agency said, adding that it conducted a site visit to determine which individuals were required to undergo screenings. For this particular case, CDA said only those found to have 'close and prolonged' contact with the staff member would have to be screened. They include both children and staff members. An onsite screening at MindChamps PreSchool was carried out on Aug 13, while a separate one for MapleBear Toa Payoh has been scheduled for Aug 15. CDA said there is a gap between exposure to the staff member and the screenings because it can take several weeks for the body to develop a detectable immune response. A second round of screenings slated for mid-September will be carried out at MapleBear Toa Payoh, 10 weeks after the date of the last exposure to the affected staff member. The agency said this is in line with national and international guidelines and would help to identify infected individuals who may not have been picked out during the first screening. MindChamps PreSchool's East Coast branch, however, will be put through only one screening because of the difference in exposure periods, CDA added. On the status of the affected staff member, CDA said the person is recovering well and currently non-infectious. The staff member is also continuing to receive treatment. Those with active cases of TB are usually non-infectious within two weeks upon being treated, it said, adding that the disease is endemic in Singapore. A disease that is endemic is one that remains permanently in the community. 'TB is curable and its spread is preventable. People with latent TB do not have symptoms and cannot spread tuberculosis to others,' said CDA. 'Parents of children identified as close contacts should follow instructions for screening for their children and, if needed, treatment.' It added: 'The child is safe to continue with normal activities unless advised otherwise. Their household members, who are not identified as close contacts, do not need to take any special precautions.' As for those who require preventive medication to reduce the risk of developing tuberculosis, CDA said it will arrange appointments and chest X-rays at the National TB Screening Centre for them. A spokesperson for the Early Childhood Development Agency (ECDA) said it was notified on July 17 about the TB diagnosis. The spokesperson said that when there is any known or suspected case of the disease, pre-schools are required to promptly inform ECDA, parents and CDA. The pre-schools will also need to implement hygiene, cleaning and disinfection measures. The spokesperson added that as part of regular health surveillance protocols, pre-schools also carry out daily temperature and health checks on all children, staff and visitors as soon as they arrive. They are also not supposed to admit any individuals who are unwell or display symptoms of infectious diseases. The Straits Times has contacted both the affected pre-schools for more information. The last time a TB screening was reported as having been conducted at a pre-school was in 2019, after an individual at a PAP Community Foundation (PCF) Sparkletots in Bukit Batok was diagnosed with the disease. Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store